Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
December 1, 2006
Does treatment of recurrent epithelial ovarian cancer with secondary debulking surgery improve survival?
secondary debulking surgery
RETROSPECTIVEGermany/Switzerlandrecurrent epithelial ovarian cancer treated with secondary debulking surgery
n=26769% stage III/IV at diagnosis86% received 1st line platinum-based chemoCGR 50%, Optimal 76%90% received post-op chemotherapyfactors associated with CGR - good performance score, early initial FIGO stage or CGR at PDS, and no ascites = 79% chance of CGRmedian f/u: 19 mosmedian OS: 45.2mos CGR vs vs 19.6 mos 1-10mm residual vs 19.7mos suboptimal (SS)
Only CGR at secondary debulking resulted in improved survival in women with recurrent epithelial ovarian cancer. These data were used in the planning of DESKTOP II, a prospective trial.